Could serum IGF-1 and IGF-2 serve as potential biomarkers in idiopathic Parkinson's disease? A correlation with disease stages

Basit Öğe Kaydı
dc.contributor.authorCakir, Ezgi Ayse
dc.contributor.authorOzyilmaz, Aysegul
dc.contributor.authorAlpay, Merve
dc.contributor.authorUyurca, Sare
dc.date.accessioned2025-10-11T20:48:39Z
dc.date.available2025-10-11T20:48:39Z
dc.date.issued2025
dc.departmentDüzce Üniversitesien_US
dc.description.abstractIntroduction Idiopathic Parkinson's Disease (IPD) is a progressive neurodegenerative disorder characterized by tremor, rigidity, akinesia, and postural instability. Dysfunction in lysosomal autophagy, involving proteins like IGF-1(insulin like growth factor) and IGF-2, contributes to neuroinflammation and neuronal death. Reliable biomarkers for IPD diagnosis and monitoring remain elusive. This study investigates serum IGF-1 and IGF-2 levels to evaluate their biomarker potential. Methods Eighty-four individuals (43 IPD patients, 41 controls) aged 18-79 were included. Diagnoses followed the UK Brain Bank Criteria; disease severity was assessed with Hoehn & Yahr (H&Y) and UPDRS scales. Serum IGF-1 and IGF-2 levels were measured using ELISA. Statistical analyses were performed using SPSS v30.0. Normality was assessed via the Shapiro-Wilk test. Based on data distribution, Independent Samples t-test, Mann-Whitney U, Chi-square, Kruskal-Wallis, Spearman correlation, and ROC analysis were applied. A p-value < 0.05 was considered statistically significant. Results Serum IGF-2 levels were significantly higher in patients compared to controls (p = 0.006), while IGF-1 levels showed no significant difference. Both IGF-1 and IGF-2 levels displayed negatively correlated with disease duration (p = 0.044 and p = 0.008). Although IGF-1 and IGF-2 levels appeared elevated at H&Y stage 2, the differences were not statistically significant. No significant associations were observed between IGF levels and UPDRS scores or medication use. Conclusion Elevated serum IGF-2 levels indicate its potential as a biomarker for IPD. These findings contribute to a better understanding of the role of IGF-1 and IGF-2 in IPD pathophysiology, suggesting that further multicenter studies are needed to clarify their diagnostic and therapeutic potential.en_US
dc.description.sponsorshipScientific Research Projects Commission of Duezce University [2020.04.03.1108]en_US
dc.description.sponsorshipThis research was supported by the Scientific Research Projects Commission of Duezce University under the project number 2020.04.03.1108.en_US
dc.identifier.doi10.1007/s13760-025-02839-3
dc.identifier.endpage1090en_US
dc.identifier.issn0300-9009
dc.identifier.issn2240-2993
dc.identifier.issue4en_US
dc.identifier.pmid40691745en_US
dc.identifier.scopus2-s2.0-105011162258en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1083en_US
dc.identifier.urihttps://doi.org/10.1007/s13760-025-02839-3
dc.identifier.urihttps://hdl.handle.net/20.500.12684/22033
dc.identifier.volume125en_US
dc.identifier.wosWOS:001532966600001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofActa Neurologica Belgicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKA_WOS_20250911
dc.subjectInsulin-like growth factorsen_US
dc.subjectIdiopathic Parkinson's diseaseen_US
dc.subjectBiomarkersen_US
dc.subjectNeuroinflammationen_US
dc.subjectLysosomal autophagyen_US
dc.titleCould serum IGF-1 and IGF-2 serve as potential biomarkers in idiopathic Parkinson's disease? A correlation with disease stagesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu